Raf Simons Presented His Fall 2018 Collection for CALVIN KLEIN 205W39NYC
CALVIN KLEIN today announced that the brand’s Chief Creative Officer, Raf Simons, presented his Fall 2018 CALVIN KLEIN 205W39NYC runway show at the American Stock Exchange in New York City last evening.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180214005869/en/
The front row at the Fall 2018 CALVIN KLEIN 205W39NYC runway show last night in New York
“This collection is an evolution of my idea of CALVIN KLEIN - of a view onto American society - but now wider, universal. It’s an allegory for a meeting of old worlds and new worlds, relating to the discovery of America, the 1960s Space Race, and the twenty-first century information age. Reflecting the notion of democracy, there is no cultural hierarchy: the mixes emancipate clothing and references from their meanings, from their own narratives, and collage them to discover something different - a different dream. More than anything else, this collection is about freedom. A word that defines America, and CALVIN KLEIN.” - Raf Simons, February 13, 2018
Titled LANDSCAPES, the Fall 2018 CALVIN KLEIN 205W39NYC show was staged in an epic and unreal terrain simultaneously recalling a cinematic soundstage. The backdrop draws on CALVIN KLEIN’S recent history, but reconfigured: fragments of Sterling Ruby’s installations for the brand appeared against parts of the nineteenth century prairie barn featured in the CALVIN KLEIN 205W39NYC Spring 2018 campaign; the barn walls are papered with billboard-scale images of the artworks by Andy Warhol used in the same collection; beside them, air-duct tubing emerges, an alien touch of the scientific or laboratorial. The floor is carpeted with deep drifts of popcorn: from a distance, it resembles snow.
The collection and venue showcased the ongoing and multi-level collaboration between CALVIN KLEIN and The Andy Warhol Foundation for the Visual Arts. Warner Bros.’ Looney Tunes characters Wile E. Coyote and Road Runner, originally shown as shorts in cinemas from 1949, are also featured on select garments. The latter recall childhood innocence, the all-important idea of American Youth, and they can also be seen as a parable of the pursuit of the American Dream.
Mr. Simons presented his Fall 2018 collection to an audience that included notable guests Nicole Kidman, Lupita Nyong’o, Isabelle Huppert, Margot Robbie, Millie Bobby Brown, A$AP Rocky, Laura Dern, Chadwick Boseman, Michael B. Jordan, Letitia Wright, Sebastian Stan, Bill Skarsgård, Lucas Hedges, Judith Light, Kyle MacLachlan, James Murphy, Sandy Brant, Cindy Sherman, Kelela, Dev Hynes, Christina Ricci, Harris Dickinson, Ashton Sanders, Alex Hibbert, Rowan Blanchard, Amandla Stenberg, Anya Taylor Joy, Rachel Brosnahan, Alfie Allen, Bernard Sumner, Dane DeHaan, Paris Jackson, Maya Hawke, Jack Kilmer, Julia Garner, Sergei Polunin, Annabelle Sciorra, Valeria Bilello, Natasha Dupeyrón, Cindy Crawford, Rande Gerber, Karlie Kloss, Carolyn Murphy, Helena Christensen, Winnie Harlow, Jelly Lin, Jessica Jung, Camila Coelho, Helena Bordon, Brian Anderson, Helena Hauff, Richie Hawtin, and Clara3000, among others.
CALVIN KLEIN is a global lifestyle brand that exemplifies bold, progressive ideals and a seductive aesthetic. We seek to thrill and inspire our audience while using provocative imagery and striking designs to ignite the senses.
Founded in 1968 by Calvin Klein and his business partner Barry Schwartz, we have built our reputation as a leader in American fashion through our clean aesthetic and innovative designs. Global retail sales of CALVIN KLEIN brand products exceeded $8 billion in 2016 and were distributed in over 110 countries. CALVIN KLEIN employs over 10,000 associates globally. We were acquired by PVH Corp. in 2003.
About PVH Corp.
With a history going back over 135 years, PVH has excelled at growing brands and businesses with rich American heritages, becoming one of the largest apparel companies in the world. We have over 35,000 associates operating in over 40 countries and over $8 billion in annual revenues. We own the iconic CALVIN KLEIN , TOMMY HILFIGER , Van Heusen , IZOD , ARROW , Speedo *, Warner’s and Olga brands, as well as the digital-centric True & Co. intimates brand, and market a variety of goods under these and other nationally and internationally known owned and licensed brands.
*The Speedo brand is licensed for North America and the Caribbean in perpetuity from Speedo International Limited.
Artwork by Andy Warhol featured on garments ©/®/™ The Andy Warhol Foundation for the Visual Arts, Inc.;
Looney Tunes and all related characters and elements © & ™ Warner Bros. Entertainment Inc.
IMAGE CREDIT – RUNWAY LOOKS: © 2018 Giovanni Giannoni
IMAGE CREDIT – CELEB PORTRAITS + FRONT ROW: © 2018 BFA.com
ADDITIONAL IMAGES AVAILABLE AT www.BFA.com
B-ROLL AVAILABLE FOR BROADCAST UPON REQUEST
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54 | Pressemelding
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr
Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00 | Pressemelding
Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third